RecruitingNot ApplicableNCT06468397

Acute Retinal Detachment Repair With the iSeelr™ Retinal Detachment Repair System

An Improved Retinal Detachment Repair Method: A First-in-human Clinical Trial of the Safety and Performance of the iSeelr™ Retinal Detachment Repair System to Seal Retinal Tears Intraoperatively


Sponsor

Photofuse Pty Ltd

Enrollment

10 participants

Start Date

Sep 13, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

This study is a first-in-human clinical trial testing a new treatment for rhegmatogenous retinal detachments. The new treatment called retinal thermofusion uses a special laser device called iSeelr™ during surgery. The benefit of the device is that it repairs retinal tears without needing a gas bubble making it quicker to recover from surgery. The study will help us determine how safe and well the device performs in repairing a retinal detachment in people.


Eligibility

Min Age: 50 Years

Inclusion Criteria8

  • Aged 50 years or older.
  • Willing and able to comply with all study requirements and visits.
  • Provided written informed consent.
  • Study Eye:
  • Recent onset as demonstrated by symptoms or diagnosis macular involving rhegmatogenous retinal detachment.
  • Detachment due to single or multiple retinal tears in the superior region of the retina
  • Fellow eye:
  • Visual acuity of 6/12 or better.

Exclusion Criteria25

  • History of medical, surgical, or other conditions that, in the opinion of the investigator, would limit study participation e.g. unstable diabetes, poorly controlled hypertension.
  • Travel limitations that could prevent review at proscribed study intervals or any other time during the study.
  • Inability to provide informed consent.
  • Anaesthetic risk factors or inability to lie supine for 1 hour.
  • Pregnant and/or breast feeding (to be confirmed on treatment day)
  • Current systemic infection
  • Current ocular infection
  • Unable to return for post-treatment visits
  • Known inability to attend the emergency department in the event of an adverse event.
  • Significant vitreous haemorrhage partially or fully obscuring detailed examination of the retina
  • Intraoperative identification of tears below the superior region in the area of retinal detachment not identified at the screening visit or during pre-operative examination. Note: Isolated retinal tears in attached retina, identified at any time are NOT an exclusion criterion and may be treated with lase as per standard of care
  • Clinical signs of PVR (+1 flare, vitreous clumps, pigment clusters on the inferior retina, rolled retinal tear edge, star-fold)
  • Myopia greater than -4 D spherical equivalent as confirmed by last refraction prior to becoming pseudophakic if cataract surgery has been performed
  • History of glaucoma or elevated intraocular pressure >21mmHg
  • Prior or current intraocular infection
  • Visual Acuity worse than 6/12
  • Myopia greater than -4D spherical equivalent or axial length greater than 26mm if known
  • Any potential sight threatening pathology in the fellow eye as determined by the investigator
  • Extensive lattice degeneration
  • Unilateral high myopia as determined by the investigator
  • Family history of retinal detachment
  • Collagen disorders such as Marfan's or Sticklers syndrome
  • History of ocular trauma
  • Evidence of any abnormality of the eye structure as determined by the investigator
  • Planned surgery during the study period

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEiSeelr™

The iSeelr™ device will be used to deliver 1940nm laser output along with low airflow to seal a retinal tear


Locations(1)

The Royal Victorian Eye and Ear Hospital (RVEEH)

East Melbourne, Victoria, Australia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06468397